ICH E6 R3 opens the next chapter for future clinical research
How the updated guideline reshapes expectations in clinical research from 2025 onwards
For years, ICH E6 has formed the backbone of Good Clinical Practice.
Each revision has raised the bar on transparency, safety, and reliability in clinical research. Now, with the arrival of ICH E6 R3, the industry embarks on a new chapter.
This update marks a shift in how trials are expected to be designed, conducted, and documented.
The new guideline challenges sponsors and CROs to place quality at the centre of their work, to plan with a sharper focus on risk, and to ensure that documentation reflects accountability and respect for the participants who make research possible.</span>
At BioStata, we see this as an opportunity to strengthen our working procedures and enhance our trial oversight, ensuring that our partners can meet these expectations with clarity and confidence.
In this blog post, we highlight some of the key areas of change and what they mean for our way of working.
A change in language reflects a change in perspective
One of the simpler but most telling updates is a linguistic matter.
The word “subjects” has been replaced with “participants”. At first glance, this may seem minor, but the change in wording signals a cultural shift that organisations cannot afford to overlook.
The new terminology reminds us that trials are built on individuals who volunteer to take part. It acknowledges their contribution and reinforces the responsibility that researchers carry.
We are updating our working procedures and communications to reflect this shift. For us, it is not about terminology alone, but about ensuring respect for participants and embedding accountability in the way trials are described, conducted, and overseen.
Quality by design becomes the foundation
Earlier revisions of ICH E6 introduced the concept of risk-based approaches, but R3 takes it one step further.
Quality is no longer something to be verified late in the process. It must be designed into the trial from the very beginning. This is what the guideline calls “quality by design”.
In practice, this means identifying what is critical to quality during planning, performing risk assessments that consider complexity, endpoints, and participant safety, and building proportionate processes around them.
Instead of applying the same level of oversight everywhere, R3 encourages organisations to focus resources where they matter most.
This way of thinking is already built into how we plan and manage trials. By aligning working procedures and oversight with quality by design, we make sure trial management remains proactive rather than reactive.
Audits come with sharper expectations
Audits have always been a cornerstone of compliance, but R3 sets new standards for what is expected.
Internal audit planning can no longer be reduced to a routine schedule. It must take into account the criticality and complexity of a trial, ensuring that higher-risk areas receive the closest scrutiny.
Another significant addition is the requirement to issue an audit certificate once an audit is completed. This serves as formal evidence that the audit has taken place and that findings are properly recorded.
The certificate is expected to be part of the trial master file, reinforcing transparency and documentation.
Our audit approach reflects this shift. By refining our working procedures, we ensure that audits are planned in a risk-based manner and that documentation, including certificates, demonstrates compliance clearly and consistentl
Handling deviations with greater urgency
Deviations are part of every trial, but ICH E6 R3 raises the bar for how they should be managed.
Non-compliance must trigger prompt and proportionate action. While minor issues can often be resolved within the team, significant problems must be escalated, and, in some cases, reported to sponsors or regulators.
Corrective and preventive action (CAPA) is not new, but R3 demands more clarity in how it is applied.
Organisations need to show they understand the root cause of non-compliance and have measures in place to prevent recurrence. This strengthens accountability and reduces the risk of repeated errors undermining trial quality.
Our trial oversight and working procedures are aligned with this principle. We ensure that deviations are not only corrected but used as opportunities to prevent recurrence and strengthen trial integrity.
What does it all mean in the bigger picture?
Perhaps the most important message from ICH E6 R3 is that it is not just another set of procedures to follow.
It is about culture. Trials must be designed and managed in a way that puts participants first, identifies risks early, and builds quality into every step.
Documentation must reflect these principles, but the real shift lies in how organisations approach their work on a daily basis.
That is why R3 is a call to change the mindset of clinical research. Organisations that adopt these principles early will not only ensure compliance but also strengthen trust with regulators, sponsors, and participants alike.
For BioStata, this means continuing to refine our working procedures and reinforcing oversight, so that every project we take on reflects these updated expectations.
Do you want a Data Science partner to help you grapple ICH E6 R3?
Your search ends here.
At BioStata, we help sponsors prepare for evolving regulatory requirements, including those outlined in ICH E6 R3. With expertise in data management, biostatistics, programming, DMCs, and submission services, we ensure clinical trial data is managed with structure, precision, and compliance.
As the industry turns this page, we are ready to support you in aligning with the new standard and keeping your trials moving forward.
Let us talk about your trial
Fill out the form, and we will contact you to schedule a meeting.